Profile data is unavailable for this security.
About the company
Astria Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for allergic and immunological diseases. The Company's lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema (HAE), a rare, debilitating and potentially life-threatening disease. Its second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis (AD). The Company owns two patent families directed to STAR-0215. The first patent family is directed to the composition of matter of its product candidate STAR-0215 and its use in treating various plasma kallikrein associated disorders including HAE. In the second patent family, the Company owns one International (PCT) patent application directed to methods of treating various plasma-kallikrein associated disorders, including HAE, with specific dosing regimens of the STAR-0215 antibody.
- Revenue in USD (TTM)0.00
- Net income in USD-72.89m
- Incorporated2008
- Employees59.00
- LocationAstria Therapeutics Inc75 State Street, Suite 1400BOSTON 02109United StatesUSA
- Phone+1 (617) 349-1971
- Fax+1 (617) 273-2637
- Websitehttps://astriatx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adlai Nortye Ltd (ADR) | 5.00m | -104.87m | 508.49m | 127.00 | -- | 6.40 | -- | 101.70 | -7.26 | -7.26 | 0.1931 | 2.15 | -- | -- | -- | 39,370.08 | -- | -- | -- | -- | -- | -- | -2,097.42 | -- | -- | -1.69 | 0.2843 | -- | -- | -- | -78.38 | -- | -- | -- |
| ProKidney Corp | 0.00 | -35.47m | 509.74m | 163.00 | -- | -- | -- | -- | -0.5683 | -0.5683 | 0.00 | -18.43 | 0.00 | -- | -- | 0.00 | -28.86 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0004 | -- | -- | -- | 67.17 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -108.30m | 511.74m | 118.00 | -- | 4.74 | -- | -- | -3.14 | -3.14 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -68.23 | -33.56 | -75.55 | -36.55 | -- | -- | -- | -941.88 | -- | -- | 0.00 | -- | -- | -- | -12.83 | -- | -3.47 | -- |
| GeneDx Holdings Corp | 221.85m | -135.02m | 512.21m | 1.00k | -- | 2.48 | -- | 2.31 | -5.25 | -5.25 | 8.60 | 7.93 | 0.4721 | 9.16 | 7.27 | 221,849.00 | -28.73 | -- | -35.07 | -- | 50.57 | 11.50 | -60.86 | -121.10 | 2.99 | -130.27 | 0.2015 | -- | -13.69 | 8.72 | 67.98 | -- | 7.77 | -- |
| Shattuck Labs Inc | 1.66m | -87.30m | 512.60m | 75.00 | -- | 3.52 | -- | 309.35 | -2.05 | -2.05 | 0.0389 | 3.06 | 0.0091 | -- | -- | 22,093.33 | -47.85 | -29.14 | -53.15 | -32.42 | -- | -- | -5,268.44 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Altimmune Inc | 426.00k | -88.45m | 517.54m | 59.00 | -- | 2.66 | -- | 1,214.87 | -1.64 | -1.64 | 0.008 | 2.75 | 0.002 | -- | 0.6636 | 7,220.34 | -42.36 | -39.62 | -45.55 | -42.58 | -- | -- | -20,762.21 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Alector Inc | 97.06m | -130.39m | 519.51m | 244.00 | -- | 3.41 | -- | 5.35 | -1.56 | -1.56 | 1.16 | 1.58 | 0.1377 | -- | 75.04 | 397,795.10 | -18.50 | -20.00 | -22.92 | -23.81 | -- | -- | -134.34 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
| Nkarta Inc | 0.00 | -117.50m | 521.46m | 150.00 | -- | 1.33 | -- | -- | -2.40 | -2.40 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -27.59 | -32.39 | -29.14 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Avid Bioservices Inc | 136.74m | -17.96m | 523.71m | 365.00 | -- | 2.91 | -- | 3.83 | -0.284 | -0.284 | 2.17 | 2.84 | 0.302 | 3.18 | 4.89 | 374,616.40 | -3.97 | 10.73 | -6.03 | 15.22 | 7.47 | 22.72 | -13.13 | 25.92 | 0.3097 | -5.04 | 0.4548 | 0.00 | 24.81 | 22.72 | -99.56 | -- | 82.90 | -- |
| Allogene Therapeutics Inc | 95.00k | -327.27m | 524.12m | 232.00 | -- | 1.01 | -- | 5,517.05 | -2.09 | -2.09 | 0.0006 | 3.04 | 0.0001 | -- | -- | 409.48 | -44.70 | -28.46 | -47.65 | -30.21 | -- | -- | -344,489.50 | -1,123.44 | -- | -- | 0.00 | -- | -39.10 | -- | 3.86 | -- | -14.06 | -- |
| Astria Therapeutics Inc | 0.00 | -72.89m | 524.42m | 59.00 | -- | 2.65 | -- | -- | -2.34 | -2.34 | 0.00 | 5.92 | 0.00 | -- | -- | 0.00 | -30.04 | -64.48 | -31.37 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
| Humacyte Inc | 0.00 | -110.78m | 525.16m | 183.00 | -- | 33.75 | -- | -- | -1.07 | -1.07 | 0.00 | 0.1307 | 0.00 | -- | -- | 0.00 | -66.63 | -- | -75.23 | -- | -- | -- | -- | -- | -- | -88.38 | 0.5819 | -- | -100.00 | -- | -825.83 | -- | -- | -- |
| Verve Therapeutics Inc | 11.76m | -200.07m | 537.95m | 255.00 | -- | 0.8764 | -- | 45.75 | -3.13 | -3.13 | 0.1832 | 7.31 | 0.0164 | -- | 3.40 | 46,109.80 | -27.94 | -- | -29.43 | -- | -- | -- | -1,701.55 | -- | -- | -- | 0.00 | -- | 505.77 | -- | -27.12 | -- | -- | -- |
| Celcuity Inc | 0.00 | -63.78m | 538.11m | 55.00 | -- | 3.22 | -- | -- | -2.70 | -2.70 | 0.00 | 5.48 | 0.00 | -- | -- | 0.00 | -34.76 | -37.32 | -36.88 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2095 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
| Korro Bio Inc | 0.00 | -81.17m | 540.04m | 101.00 | -- | 2.75 | -- | -- | -68.38 | -68.38 | 0.00 | 21.20 | 0.00 | -- | -- | 0.00 | -47.34 | -31.55 | -53.69 | -36.48 | -- | -- | -- | -365.87 | -- | -- | 0.00 | -- | -- | -- | 0.5001 | -- | 78.21 | -- |
Data as of May 03 2024. Currency figures normalised to Astria Therapeutics Inc's reporting currency: US Dollar USD
51.86%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 01 Feb 2024 | 6.49m | 11.81% |
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 4.80m | 8.75% |
| RA Capital Management LPas of 01 Feb 2024 | 4.41m | 8.04% |
| Fairmount Funds Management LLCas of 31 Dec 2023 | 3.55m | 6.47% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 2.04m | 3.71% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 2.00m | 3.64% |
| Armistice Capital LLCas of 31 Dec 2023 | 1.58m | 2.87% |
| Affinity Asset Advisors LLCas of 31 Dec 2023 | 1.47m | 2.67% |
| Sphera Funds Management Ltd.as of 31 Dec 2023 | 1.15m | 2.10% |
| Saturn V Capital Management LLCas of 31 Dec 2023 | 990.66k | 1.80% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
